Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Income from Continuing Operations (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Income from Continuing Operations for 17 consecutive years, with 7900000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 81.41% to 7900000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 365900000.0 through Dec 2025, down 187.43% year-over-year, with the annual reading at 365900000.0 for FY2025, 187.43% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 7900000.0 at Myriad Genetics, up from 27400000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 24600000.0 in Q3 2021, with the low at 330500000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 44785000.0, with a median of 29300000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations skyrocketed 261.84% in 2021, then plummeted 800.54% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 7600000.0 in 2021, then crashed by 456.58% to 42300000.0 in 2022, then increased by 26.24% to 31200000.0 in 2023, then plummeted by 36.22% to 42500000.0 in 2024, then surged by 81.41% to 7900000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 7900000.0, 27400000.0, and 330500000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.